Emerging personalized approaches for the management of advanced urothelial carcinoma

Che Kai Tsao; Benjamin A. Gartrell; William K. Oh; Matthew D. Galsky

doi:10.1586/era.12.141

Emerging personalized approaches for the management of advanced urothelial carcinoma

Che Kai Tsao, Benjamin A. Gartrell, William K. Oh, Matthew D. Galsky

Oncology

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

Original language	English (US)
Pages (from-to)	1537-1543
Number of pages	7
Journal	Expert Review of Anticancer Therapy
Volume	12
Issue number	12
DOIs	https://doi.org/10.1586/era.12.141
State	Published - Dec 2012

Keywords

biomarker
bladder cancer
chemotherapy
neoadjuvant therapy
personalized medicine
urothelial carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/era.12.141

Cite this

@article{000a6f6232554a1e992cdd16d62dc65c,

title = "Emerging personalized approaches for the management of advanced urothelial carcinoma",

abstract = "Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.",

keywords = "biomarker, bladder cancer, chemotherapy, neoadjuvant therapy, personalized medicine, urothelial carcinoma",

author = "Tsao, {Che Kai} and Gartrell, {Benjamin A.} and Oh, {William K.} and Galsky, {Matthew D.}",

year = "2012",

month = dec,

doi = "10.1586/era.12.141",

language = "English (US)",

volume = "12",

pages = "1537--1543",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "12",

}

TY - JOUR

T1 - Emerging personalized approaches for the management of advanced urothelial carcinoma

AU - Tsao, Che Kai

AU - Gartrell, Benjamin A.

AU - Oh, William K.

AU - Galsky, Matthew D.

PY - 2012/12

Y1 - 2012/12

N2 - Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

AB - Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

KW - biomarker

KW - bladder cancer

KW - chemotherapy

KW - neoadjuvant therapy

KW - personalized medicine

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84871501689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871501689&partnerID=8YFLogxK

U2 - 10.1586/era.12.141

DO - 10.1586/era.12.141

M3 - Review article

C2 - 23253220

AN - SCOPUS:84871501689

SN - 1473-7140

VL - 12

SP - 1537

EP - 1543

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 12

ER -

Emerging personalized approaches for the management of advanced urothelial carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this